Five-Year ADlong Data on Lebrikizumab for Atopic Dermatitis Presented
Lebrikizumab reaches a five-year follow-up milestone in the ADlong extension study for atopic dermatitis, with Stephan Weidinger, MD, PhD, unpacking the long-term data for clinicians.